A recent study has reported that breast cancer patients with a high burden of rare variants in the transporter gene ABCC1 (MRP1) have shorter disease-specific survival than patients with a low variant burden after therapy with the MRP1 substrates cyclophosphamide and doxorubicin [5]. Here, ABCC1 is linked to breast carcinoma.